Breast Cancer Virtual Journal Club: Eribulin as Single-Agent Treatment for Metastatic Breast Cancer

Breast Cancer Virtual Journal Club
Eribulin as Single-Agent Treatment for Metastatic Breast Cancer

Expert perspectives with Javier Cortés, MD, PhD, and Christopher Twelves, MD.

This independent medical education activity features an expert interview with Javier Cortés, MD, PhD, and Christopher Twelves, MD, focusing on the recent manuscript covering the EMBRACE trial of eribulin versus treatment of physician’s choice in metastatic breast cancer (Cortes J, et al. Lancet. 2011 March 3 [Epub ahead of print]).

Drs Cortés and Twelves briefly discuss the EMBRACE trial and how results of this trial will impact clinical practice.

Audience
The information on this site is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before accessing the Webcast and slides. This site may contain information on products outside the approved indications where you practice.

Support
This educational activity is supported by Eisai Inc.

Click here
to view Webcast

Featured Experts

Speaker

Javier Cortés, MD, PhD
Vall d’Hebron University Hospital
Barcelona, Spain

Interviewer

Christopher Twelves, MD
University of Leeds and
St James University Hospital
Leeds, United Kingdom

Activity Date
This Webcast is available from 14 March 2011 to 14 March 2012.

Breast Cancer Virtual Journal Club

Audience

Support

Featured Experts

Activity Date